| Literature DB >> 27357644 |
Tsuimin Tsai1, Chen-Yu Kao2,3, Chun-Liang Chou2, Lu-Chun Liu2, Tz-Chong Chou4,5.
Abstract
Magnolol has shown inhibitory effects on NO production and TNF-alpha production in lipopolysaccharide (LPS)-activated macrophages and LPS-induced acute lung injury; however, the poor solubility of magnolol has hindered its clinical success. In this study, magnolol-loaded microparticles were prepared via single emulsion method from a polyketal polymer, termed PK3. The particle sizes of magnolol-loaded PK3 microparticle is 3.73 ± 0.41 μm, and was suitable for phagocytosis by macrophages and pulmonary drug delivery. PK3 microparticles exhibited excellent biocompatibility both in vitro and in vivo. More importantly, intratracheal delivery of these magnolol-loaded microparticles significantly reduced the lung inflammatory responses at low dosage of magnolol (0.5 mg/kg), and have great clinical potential in treating acute lung injury.Entities:
Keywords: Magnolol; acute lung injury; anti-inflammatory. pulmonary drug delivery; polyketal microparticles
Mesh：
Substances：
Year: 2016 PMID： 27357644 DOI： 10.1080/02652048.2016.1202344
Source DB: PubMed Journal: J Microencapsul ISSN： 0265-2048 Impact factor: 3.142